Indivior reported 40M in Cost of Sales for its fiscal semester ending in March of 2026.





Cost Of Sales Change Date
AstraZeneca USD 2.52B 2.73B Jun/2026
Cassava Sciences USD 3.96M 1.16M Sep/2025
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Roche Holding CHF 7.85B 630M Jun/2026
West Pharmaceutical Services USD 543.1M 5.4M Jun/2026